Gilenya fingolimod: Phase III data

The double-blind, international Phase III INFORMS trial in 970 patients ages 25-69 with PPMS showed that 0.5 mg Gilenya for ³3 years missed the primary endpoint of reducing the risk of 3-month sustain...